Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | NAMPT | P43490 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CPN1 | P15169 | 2/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12448284 | 0.84 | ALDH1A1 (0.35) | BTKKCNQ3KCNQ2PIK3CDNAMPT | |
| SCHEMBL12449196 | 0.84 | ALDH1A1 (0.35) | BTKKCNQ3KCNQ2PIK3CDNAMPT | |
| SCHEMBL12448280 | 0.84 | ALDH1A1 (0.35) | BTKKCNQ3KCNQ2PIK3CDNAMPT | |
| SCHEMBL12448276 | 0.82 | ALDH1A1 (0.38) | PIK3CDHSD17B10ALDH1A1 | |
| SCHEMBL25094200 | 0.82 | PDE4B (0.35) | BTKPIK3CDNAMPTHSD11B1PDE4B | |
| SCHEMBL12448268 | 0.82 | PDE4B (0.35) | BTKPIK3CDNAMPTHSD11B1PDE4B | |
| SCHEMBL17660647 | 0.82 | PDE4B (0.35) | BTKPIK3CDNAMPTHSD11B1PDE4B | |
| SCHEMBL17306133 | 0.81 | PIK3CD (0.36) | BTKPIK3CDHSD17B10OPRK1 | |
| SCHEMBL17660633 | 0.81 | NPC1 (0.38) | BTKPIK3CDALDH1A1POLB | |
| SCHEMBL17306173 | 0.79 | IRAK4 (0.39) | PIK3CDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | BTK 4551/4885KCNQ3 1489/4885KCNQ2 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.